All issues

AtaiBeckley

Every issue covering AtaiBeckley.

8 issues

• 2026-09-29No. 16

  Initiated in Q2. Unregistered at the end of Q3.

  • TRIALS
  • DEALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • CYBIN
• 2026-09-22No. 15

  The CVR is an option, and Lilly holds it

  • DEALS
  • REGULATORY
  • TRIALS
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • ABBVIE
  • OTSUKA
• 2026-09-15No. 14

  Five countries, one regulator.

  • TRIALS
  • DEALS
  • REGULATORY
  • DEFINIUM
  • LILLY
  • ATAIBECKLEY
  • COMPASS
  • GH
• 2026-09-01No. 12

  Lilly’s depression trial went from one approval to four in seven days.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • ATAI-THERAPEUTICS
• 2026-08-25No. 11

  Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.

  • TRIALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
  • BECKLEY-PSYTECH
  • REGION-SKANE
• 2026-07-21No. 7

  Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine

  • DEALS
  • REGULATORY
  • LILLY
  • ATAIBECKLEY
• 2026-06-16No. 2

  Blind the psilocybin trials in TRD, and the effect shrinks

  • RESEARCH
  • TRIALS
  • ATAIBECKLEY
• 2026-06-11

  European Psychedelic Medicine: H1 2026 in Review

  • RESEARCH
  • DEALS
  • COMPASS
  • ATAIBECKLEY
  • BECKLEY-PSYTECH
  • GH